Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC

被引：4

作者：

Bilen, M. A. ^{[1
]}

Xi, A. D. ^{[2
]}

Wong, A. ^{[2
]}

Schroeder, A. ^{[3
]}

Kim, R. ^{[4
]}

Liu, F. X. ^{[5
]}

Peng, J. ^{[3
]}

Robinson, S. ^{[2
]}

Bhanegaonkar, A. ^{[6
]}

机构：

[1] Emory Univ, Oncol Dept, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Avalere Hlth, Hlth Econ & Adv Analyt, Washington, DC USA

[3] Avalere Hlth, Commercializat & Regulatory Strategy, Washington, DC USA

[4] HEOR, Pfizer, New York, NY USA

[5] EMD Serono Inc, US Hlth Econ & Outcomes Res, Darmstadt, Germany

[6] EMD Serono Inc, North Amer Med Affairs, US Hlth Econ & Outcomes Res, Oncol, Darmstadt, MA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.097

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

701P

引用

页码：S713 / S713

页数：1